A consensus conference to define the utility of advanced infectious disease diagnostics in solid organ transplant recipients

The last decade has seen an explosion of advanced assays for the diagnosis of infectious diseases, yet evidence‐based recommendations to inform their optimal use in the care of transplant recipients are lacking. A consensus conference sponsored by the American Society of Transplantation (AST) was co...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of transplantation Vol. 22; no. 12; pp. 3150 - 3169
Main Authors Azar, Marwan M., Turbett, Sarah, Gaston, David, Gitman, Melissa, Razonable, Raymund, Koo, Sophia, Hanson, Kimberly, Kotton, Camille, Silveira, Fernanda, Banach, David B., Basu, Sankha S., Bhaskaran, Archana, Danziger‐Isakov, Lara, Bard, Jennifer Dien, Gandhi, Ronak, Hanisch, Benjamin, John, Teny M., Odom John, Audrey R., Letourneau, Alyssa R., Luong, Me‐Linh, Maron, Gabriela, Miller, Steve, Prinzi, Andrea, Schwartz, Ilan, Simner, Patricia, Kumar, Deepali
Format Journal Article
LanguageEnglish
Published United States Elsevier Limited 01.12.2022
Subjects
Online AccessGet full text
ISSN1600-6135
1600-6143
1600-6143
DOI10.1111/ajt.17147

Cover

More Information
Summary:The last decade has seen an explosion of advanced assays for the diagnosis of infectious diseases, yet evidence‐based recommendations to inform their optimal use in the care of transplant recipients are lacking. A consensus conference sponsored by the American Society of Transplantation (AST) was convened on December 7, 2021, to define the utility of novel infectious disease diagnostics in organ transplant recipients. The conference represented a collaborative effort by experts in transplant infectious diseases, diagnostic stewardship, and clinical microbiology from centers across North America to evaluate current uses, unmet needs, and future directions for assays in 5 categories including (1) multiplex molecular assays, (2) rapid antimicrobial resistance detection methods, (3) pathogen‐specific T‐cell reactivity assays, (4) next‐generation sequencing assays, and (5) mass spectrometry‐based assays. Participants reviewed and appraised available literature, determined assay advantages and limitations, developed best practice guidance largely based on expert opinion for clinical use, and identified areas of future investigation in the setting of transplantation. In addition, attendees emphasized the need for well‐designed studies to generate high‐quality evidence needed to guide care, identified regulatory and financial barriers, and discussed the role of regulatory agencies in facilitating research and implementation of these assays. Findings and consensus statements are presented. This meeting report summarizes findings from an AST‐sponsored consensus conference to define best practice uses, unmet needs and future directions for advanced infectious diseases diagnostics in solid organ transplant recipients.
Bibliography:This manuscript is a work product of the American Society of Transplantation's Transplant Diagnostics Community of Practice in collaboration with the Infectious Diseases Community of Practice.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1600-6135
1600-6143
1600-6143
DOI:10.1111/ajt.17147